Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + paclitaxel + trastuzumab
- Development stage
- Preclinical
- Lead developer
- Jiangsu Hengrui Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
This combination involves **apatinib**, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2); **paclitaxel**, a taxane that disrupts microtubule function in cancer cells; and **trastuzumab**, a monoclonal antibody targeting the HER2 receptor. It is used in treating HER2-positive breast cancer, particularly in cases with brain metastases.
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on apatinib + paclitaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + paclitaxel + trastuzumab.